Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maureen Leehey

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Parkinsonism & Related Disorders|December 27, 2014
Parkinson's disease severity and use of dopaminergic medicationsJohn Y Fang, Adriana Pérez, Chadwick W Christine, et al.
Neurology|October 4, 2017
Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scoresMaureen Leehey, Sheng Luo, Saloni Sharma, et al.
American Journal of Human Genetics|March 15, 2003
Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlatesSébastien Jacquemont, Randi J Hagerman, Maureen Leehey, et al.
Clinical Interventions in Aging|August 9, 2008
Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problemsRandi J Hagerman, Deborah A Hall, Sarah Coffey, et al.
Journal of Medical Genetics|June 14, 2022
The International Fragile X Premutation Registry: building a resource for research and clinical trial readinessDavid Hessl, Hilary Rosselot, Robert Miller, et al.
Journal of Parkinson'S Disease|December 3, 2016
Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1Robert A Hauser, Ruosha Li, Adriana Pérez, et al.
JAMA|February 11, 2015
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial, Karl Kieburtz, Barbara C Tilley, et al.
JAMA|September 14, 2021
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial, Michael A Schwarzschild, Alberto Ascherio, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Parkinsonism & Related Disorders|December 27, 2014
Parkinson's disease severity and use of dopaminergic medicationsJohn Y Fang, Adriana Pérez, Chadwick W Christine, et al.
Neurology|October 4, 2017
Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scoresMaureen Leehey, Sheng Luo, Saloni Sharma, et al.
American Journal of Human Genetics|March 15, 2003
Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlatesSébastien Jacquemont, Randi J Hagerman, Maureen Leehey, et al.
Clinical Interventions in Aging|August 9, 2008
Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problemsRandi J Hagerman, Deborah A Hall, Sarah Coffey, et al.
Journal of Medical Genetics|June 14, 2022
The International Fragile X Premutation Registry: building a resource for research and clinical trial readinessDavid Hessl, Hilary Rosselot, Robert Miller, et al.
Journal of Parkinson'S Disease|December 3, 2016
Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1Robert A Hauser, Ruosha Li, Adriana Pérez, et al.
JAMA|February 11, 2015
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial, Karl Kieburtz, Barbara C Tilley, et al.
JAMA|September 14, 2021
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial, Michael A Schwarzschild, Alberto Ascherio, et al.
Pageof 2